Metabolomic Deficiencies Characteristic of Chronic Fatigue Syndrome

mitochondriats175461301_1060357.jpg

Clinical Pain Advisor — 2016

Cindy Lampner

In a study designed to test the utility of targeted metabolomics in the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), researchers identified a unique chemical signature that differentiates affected patients from healthy individuals.

The study, led by Dr Robert K. Naviaux, MD, PhD of The Mitochondrial and Metabolic Disease Center at the University of California’s San Diego School of Medicine, was published August 29 in the Proceedings of the National Academy of Sciences in the United States .1

Ronald W. Davis, PhD, director of Stanford Chronic Fatigue Syndrome Research Center of Stanford University School of Medicine commented on the findings of Dr Naviaux’s group on the the Open Medicine Foundation website, where he serves as director of the Scientific Advisory Board.

Published in Clinical Pain Advisor: Read the full article

Previous
Previous

Bernard Raxlen, MD, to Receive Pioneer in Lyme Award

Next
Next

Santa Rosa doctor’s study offers new insight into chronic fatigue syndrome